• doi: 10.5489/cuaj.775
• Can Urol Assoc J. 2010 Feb; 4(1): 49–53.

Reem J. Al-Bareeq, MD, MRCSI, CABU, A. Andrew Ray, MS, MD, FRCSC, Linda Nott, RN, Stephen E. Pautler, BSc, MD, FRCSC, and Hassan Razvi, MD, FRCSC

Abstract

Objective:

To determine whether Dong Quai, a Chinese herbal compound purported to be efficacious in treating menopausal vasomotor symptoms, has a therapeutic benefit in treating hot flashes among prostate cancer patients receiving androgen deprivation therapy.

Methods:

A randomized double-blind placebo controlled trial was conducted involving 22 men receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer with bothersome hot flashes. After recording a baseline log of the frequency, duration and severity of daily hot flashes, patients were randomly assigned in a 1:1 ratio to receive daily placebo or Dong Quai for 3 months. Vasomotor and adverse events were recorded daily. Blood work including serum prostate-specific antigen (PSA), international normalized ratio of prothrombin time and partial thromoboplastin time were recorded at baseline and at the termination of the study.

Results:

Seventeen of the 22 patients enrolled completed the trial. Baseline vasomotor duration and severity were equivalent between the groups, however the number of hot flashes were significantly more in the Dong Quai group (p = 0.02). With respect to the change in number of hot flashes per day, there was a slight decrease in the mean number among the Dong Quai group which was insignificant. The absolute change and average percentage change in perceived hot flash severity was similar in both groups. There was no significant decrease in the duration of the hot flashes between the 2 groups. Disease progression based on either PSA increase or change in digital rectal exam was not observed in any patient.

Dong Quai – LIFE FORCE HEALTH CENTER

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2811999/